| # | Title | Journal | Year | Citations |
|---|
| 1 | Renal cell carcinoma | Nature Reviews Disease Primers | 2017 | 1,727 |
| 2 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | Lancet Oncology, The | 2020 | 330 |
| 3 | Evaluating Mesorectal Lymph Nodes in Rectal Cancer Before and After Neoadjuvant Chemoradiation Using Thin-Section T2-Weighted Magnetic Resonance Imaging | International Journal of Radiation Oncology Biology Physics | 2008 | 126 |
| 4 | Fibroblast growth factor receptors, developmental corruption and malignant disease | Carcinogenesis | 2013 | 122 |
| 5 | Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group | Annals of Surgical Oncology | 2021 | 105 |
| 6 | The treatment of advanced renal cell cancer with high-dose oral thalidomide | British Journal of Cancer | 2001 | 102 |
| 7 | Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reporting | European Journal of Cancer | 2016 | 99 |
| 8 | The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 | Annals of Oncology | 2009 | 94 |
| 9 | An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer | Annals of Oncology | 2010 | 75 |
| 10 | The T cell differentiation landscape is shaped by tumour mutations in lung cancer | Nature Cancer | 2020 | 74 |
| 11 | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma | Annals of Oncology | 2014 | 68 |
| 12 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma | British Journal of Cancer | 2000 | 49 |
| 13 | Potential of Surface-Coil MRI for Staging of Esophageal Cancer | American Journal of Roentgenology | 2006 | 46 |
| 14 | Potential role of immunotherapy in advanced non-small-cell lung cancer | OncoTargets and Therapy | 2017 | 46 |
| 15 | Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II Study | Clinical Lymphoma and Myeloma | 2008 | 41 |
| 16 | The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib | Expert Review of Anticancer Therapy | 2019 | 31 |
| 17 | Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials | Medical Oncology | 2013 | 30 |
| 18 | The treatment of advanced renal cell cancer with high-dose oral thalidomide | British Journal of Cancer | 2001 | 25 |
| 19 | Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors | Journal of Pain and Symptom Management | 2016 | 24 |
| 20 | Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma? | Frontiers in Oncology | 2012 | 22 |
| 21 | JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) | Annals of Oncology | 2018 | 20 |
| 22 | Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab | | 2021 | 16 |
| 23 | Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria | European Journal of Cancer | 2022 | 16 |
| 24 | A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) | Annals of Oncology | 2016 | 15 |
| 25 | Cardiac complications and manifestations of chemotherapy for cancer | Heart | 2014 | 14 |
| 26 | Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy | Current Opinion in Immunology | 2022 | 14 |
| 27 | A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules | EBioMedicine | 2022 | 14 |
| 28 | Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma | ESMO Open | 2018 | 12 |
| 29 | Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) | ESMO Open | 2016 | 11 |
| 30 | Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial | Clinical Oncology | 2020 | 11 |
| 31 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma | British Journal of Cancer | 2021 | 10 |
| 32 | Tropomyosin receptor kinase inhibitors in the management of sarcomas | Current Opinion in Oncology | 2020 | 9 |
| 33 | Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases | Human Molecular Genetics | 2022 | 9 |
| 34 | Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases | American Journal of Roentgenology | 2021 | 8 |
| 35 | Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimens | European Journal of Cancer | 2022 | 8 |
| 36 | Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial | Annals of Oncology | 2018 | 7 |
| 37 | Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy | Head and Neck | 2019 | 6 |
| 38 | The evolving background for high-dose treatment for myeloma | Bone Marrow Transplantation | 2007 | 5 |
| 39 | Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data | Frontiers in Oncology | 2015 | 5 |
| 40 | Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond | Lung Cancer | 2021 | 4 |
| 41 | Future challenges | Bone Marrow Transplantation | 2007 | 3 |
| 42 | Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins | Acta Oncológica | 2021 | 3 |
| 43 | A tale of two tumours and a plea for progress | Lancet Oncology, The | 2012 | 2 |
| 44 | PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma | Annals of Oncology | 2018 | 2 |
| 45 | Training South African clinician-scientists: Lessons from the University of Cape Town’s intercalated programme | South African Medical Journal | 2019 | 2 |
| 46 | Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases | European Journal of Cancer | 2021 | 2 |
| 47 | Tracking down tumor-specific T cells | Cancer Cell | 2022 | 2 |
| 48 | An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves | Cancers | 2022 | 2 |
| 49 | Treatment of recurrent or metastatic renal cell carcinoma | Expert Review of Anticancer Therapy | 2004 | 1 |
| 50 | Academically led clinical trials: challenges and opportunities | Annals of Oncology | 2015 | 1 |
